No Data
No Data
Chenguang Biotech Group (300138.SZ): Has repurchased 7.79% of its shares so far.
Chenguang Biotech Group (300138.SZ) announced that as of July 31, 2024, the company repurchased 41,497,698 shares through a repurchase special securities account in a centralized competitive transaction, with a turnover of RMB 432,801,274.66 (excluding transaction costs). This repurchase accounts for 7.79% of the total share capital of the company, and the highest and lowest transaction prices for this repurchase of shares are 14 yuan/share and 7.63 yuan/share respectively. This repurchase meets the requirements of the company's share repurchase plan and relevant laws and regulations.
Chenguang Biotech Group (300138.SZ): Obtained four trademark registration certificates and patent certificates in total.
Chenguang Biotech Group (300138.SZ) announced on August 2 that the company has officially obtained the trademark registration certificate and patent certificate issued by the State Intellectual Property Office in recent days. The specific situation is as follows: 1. Obtaining trademark registration; 2. Obtaining patent certificate.
In the first quarter of 2024, cottonseed business revenue accounted for 48.50% of Chenguang Biotech Group's (300138.SZ) business.
Chenguang Biotech Group (300138.SZ) stated on an investor interaction platform on August 1st that the company's cottonseed products and soybean products have similar downstream applications, and cottonseed protein and cottonseed oil will be affected by changes in the prices of the CSI Commodity Equity Index and soybean oil. In Q1 2024, cottonseed business revenue accounted for 48.50% of the total revenue. Due to the downward market and changes in the fair value of derivative products, Q1 cottonseed business suffered significant losses, which correspondingly affected the overall business profit, leading to a year-on-year decrease.
Chenguang Biotech Group (300138.SZ): Has cumulatively repurchased 7.05% of its shares.
Chenguang Biotech Group (300138.SZ) announced on July 5th that as of July 4th, 2024, the company repurchased 37,548,998 shares of its own stock through a buyback special securities account using centralized bidding trading method, with a transaction amount of RMB 400,804,580.36 (excluding transaction costs). The proportion of shares repurchased this time accounted for 7.05% of the company's total share capital. The highest fill price for the buyback shares was 14 yuan/share, and the lowest fill price was 8.13 yuan/share.
Chenguang Biotech Group (300138.SZ): The ginkgo leaf business is still in the expansion phase, with revenue accounting for less than 1% of the total revenue.
Chenguang Biotech Group (300138.SZ) stated on the investor platform that the company's traditional chinese medicine ginkgo leaf products mainly include silver ginkgo leaf blades, health supplements of ginkgo leaf red yeast capsules, and medicinal ginkgo leaf extracts. This category of products is in the business expansion period, and related business revenue accounts for less than 1% of the company's overall revenue.
Chenguang Biotech Group (300138.SZ): has accumulated repurchased 6.96% of its shares.
Chenguang Biotech Group (300138.SZ) announced that as of June 30, 2024, the company repurchased 37,103,398 shares through a repurchase dedicated securities account in a centralized bidding trading manner, with a deal amount of CNY 397,065,025.36 (excluding transaction costs). This repurchase accounts for 6.96% of the company's total share capital. The highest fill price of this repurchased shares was 14 yuan/share and the lowest fill price was 8.13 yuan/share.
No Data